$95.41
1.92%
NYSE, Oct 10, 10:02 pm CET
ISIN
US1011371077
Symbol
BSX

Boston Scientific Stock price

$95.41
-9.82 9.33% 1M
+2.77 2.99% 6M
+6.09 6.82% YTD
+9.21 10.68% 1Y
+55.77 140.69% 3Y
+53.44 127.33% 5Y
+78.47 463.22% 10Y
+71.61 300.88% 20Y
NYSE, Closing price Fri, Oct 10 2025
-1.87 1.92%

Key metrics

Basic
Market capitalization
$141.4b
Enterprise Value
$152.4b
Net debt
$11.1b
Cash
$534.0m
Shares outstanding
1.5b
Valuation (TTM | estimate)
P/E
56.8 | 31.7
P/S
7.6 | 7.0
EV/Sales
8.2 | 7.6
EV/FCF
43.8
P/B
6.3
Financial Health
Equity Ratio
55.3%
Return on Equity
8.5%
ROCE
9.5%
ROIC
7.4%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$18.5b | $20.1b
EBITDA
$4.3b | $6.1b
EBIT
$3.5b | $5.5b
Net Income
$2.5b | $4.5b
Free Cash Flow
$3.5b
Growth (TTM | estimate)
Revenue
21.5% | 19.8%
EBITDA
21.1% | 57.7%
EBIT
26.4% | 83.1%
Net Income
37.0% | 140.6%
Free Cash Flow
89.1%
Margin (TTM | estimate)
Gross
68.3%
EBITDA
23.4% | 30.4%
EBIT
18.7%
Net
13.5% | 22.2%
Free Cash Flow
18.8%
More
EPS
$1.7
FCF per Share
$2.4
Short interest
1.3%
Employees
53k
Rev per Employee
$320.0k
Show more

Is Boston Scientific a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Boston Scientific Stock Analysis

Unlock Scores for Free

Analyst Opinions

41 Analysts have issued a Boston Scientific forecast:

38x Buy
93%
3x Hold
7%

Analyst Opinions

41 Analysts have issued a Boston Scientific forecast:

Buy
93%
Hold
7%

Financial data from Boston Scientific

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
18,494 18,494
21% 21%
100%
- Direct Costs 5,862 5,862
24% 24%
32%
12,632 12,632
20% 20%
68%
- Selling and Administrative Expenses 6,487 6,487
19% 19%
35%
- Research and Development Expense 1,835 1,835
25% 25%
10%
4,331 4,331
21% 21%
23%
- Depreciation and Amortization 874 874
4% 4%
5%
EBIT (Operating Income) EBIT 3,457 3,457
26% 26%
19%
Net Profit 2,505 2,505
37% 37%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Boston Scientific directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Boston Scientific Stock News

Positive
Seeking Alpha
4 days ago
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasin...
Neutral
Proactive Investors
5 days ago
Citi analysts stressed being ‘cautious' on US medical technology stocks entering the third quarter, as the sector tends to underperform in September and October before recovering in November.   In a note to clients on Tuesday, the analysts wrote that the sector was hit particularly hard this year as investors rotated out of healthcare and into technology.
Neutral
Seeking Alpha
12 days ago
Boston Scientific Corporation (NYSE:BSX ) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President & CEO Arthur Butcher - Executive VP and Group President of MedSurg & Asia Pacific Jim Cassidy Meghan Scanlon Adam Smith Brian Dunkin Joseph Fitzgerald - Executive VP & Group President of Cardiolog...
More Boston Scientific News

Company Profile

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Head office United States
CEO Michael Mahoney
Employees 53,000
Founded 1979
Website www.bostonscientific.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today